7-nitro-1-(phenylsulfonyl)-1H-indole

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 7-nitro-1-(phenylsulfonyl)-1H-indole
• 英文别名: 1-(Benzenesulfonyl)-7-nitroindole；1-(benzenesulfonyl)-7-nitroindole
• 化学式: C₁₄H₁₀N₂O₄S
• 分子量: 302.31
• InChiKey: OTJHBOZHRGJJHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  93.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-nitro-1-(phenylsulfonyl)-1H-indole 在 盐酸 、 4-二甲氨基吡啶 、 叔丁基锂 、 copper(II) sulfate 、 sodium hydroxide 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 正戊烷 为溶剂， 反应 3.5h， 生成 tert-butyl (2-(4-methyl-1H-indole-2-carbonyl)-1H-indol-7-yl)carbamate
  参考文献：
  名称：

  A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia

  摘要：

  Mutants of the FLT3 receptor tyrosine kinase (RTK) with duplications in the juxtamembrane domain (FLT3-ITD) act as drivers of acute myeloid leukemia (AML). Potent tyrosine kinase inhibitors (TKi) of FLT3-ITD entered clinical trials and showed a promising, but transient success due to the occurrence of secondary drug-resistant AML clones. A further caveat of drugs targeting FLT3-ITD is the co-targeting of other RTKs which are required for normal hematopoiesis. This is observed quite frequently. Therefore, novel drugs are necessary to treat AML effectively and safely. Recently bis(1H-indol-2-yl)methanones were found to inhibit FLT3 and PDGFR kinases. In order to optimize these agents we synthesized novel derivatives of these methanones with various substituents. Methanone 16 and its carbamate derivative 17b inhibit FLT3-ITD at least as potently as the TKi AC220 (quizartinib). Models indicate corresponding interactions of 16 and quizartinib with FLT3. The activity of 16 is accompanied by a high selectivity for FLT3-ITD. (c) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112232
• 作为产物：
  描述：

  7-硝基吲哚 、 苯磺酰氯 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 以95.67 %的产率得到7-nitro-1-(phenylsulfonyl)-1H-indole
  参考文献：
  名称：

  COMPOUNDS TARGETING Y220C MUTANT OF P53

  摘要：

  The present invention discloses compounds of formula (I) which can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. Also provided are processes for the synthesis and use of the compounds of formula (I).

  公开号：

  WO2024041503A1

文献信息

• [EN] SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS<br/>[FR] SYNTHÈSE, PHARMACOLOGIE ET UTILISATION DE NOUVEAUX INHIBITEURS SÉLECTIFS DE LA TYROSINE KINASE 3 DE TYPE FMS FLT3 (FLT3)
  申请人：UNIV REGENSBURG

  公开号：WO2019034538A1

  公开（公告）日：2019-02-21

  The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the compounds and methods of treatment.

  本发明涉及式(I)的小分子化合物及其作为FLT3抑制剂用于治疗各种疾病，如急性髓系白血病（AML）。本发明还涉及合成这些化合物的方法和治疗方法。
• Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors
  申请人：UNIVERSITÄT REGENSBURG

  公开号：US11384076B2

  公开（公告）日：2022-07-12

  The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the compounds and methods of treatment.

  本发明涉及式（I）的小分子化合物及其作为FLT3抑制剂用于治疗各种疾病，如急性髓性白血病（AML）。本发明进一步涉及化合物的合成方法和治疗方法。
• SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS
  申请人：UNIVERSITÄT REGENSBURG

  公开号：US20200190075A1

  公开（公告）日：2020-06-18

  The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the compounds and methods of treatment.
• [EN] COMPOUNDS TARGETING MUTANT OF P53<br/>[FR] COMPOSÉS CIBLANT UN MUTANT DE P53
  申请人：[en]JACOBIO PHARMACEUTICALS CO., LTD.

  公开号：WO2023016434A1

  公开（公告）日：2023-02-16

  Provided are compounds of formula (I) which can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. Also provided are pharmaceutical compositions comprising the compounds, methods of preparing the compounds and the use in the manufacture of medicaments for preventing or treating a disease or condition related to p53 mutants.
• COMPOUNDS TARGETING Y220C MUTANT OF P53
  申请人：[en]JACOBIO PHARMACEUTICALS CO., LTD.

  公开号：WO2024041503A1

  公开（公告）日：2024-02-29

  The present invention discloses compounds of formula (I) which can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. Also provided are processes for the synthesis and use of the compounds of formula (I).